Norpace

Product NDC: 68151-0527
11-digit product format: 681510527
Labeler code: 68151
Product ID: 68151-0527_ab01df3a-64fa-41c8-a5f3-e71003d5b298
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: disopyramide phosphate
Dosage form: CAPSULE, GELATIN COATED
Route: ORAL
Labeler: Carilion Materials Management
Application: NDA018655
Marketing category: NDA
Marketing start: 1982-07-20
Marketing end: 0000-00-00
Substance: DISOPYRAMIDE PHOSPHATE
Active strength: 150 mg/1
Pharmacologic classes: Antiarrhythmic [EPC]
NDC exclude flag: E
Listing certified through: 2018-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	68151-0527		I	Inactivated by FDA		2026-08-07
excluded package	package	68151-0527	68151-0527-3	I	Inactivated by FDA		2026-08-07

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 44 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	68151-0527-3	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	68151-0527-3	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	68151-0527-3	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	68151-0527-3	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	68151-0527-3	I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	68151-0527-3	I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	68151-0527-3	I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	68151-0527-3	I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	68151-0527-3	I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	68151-0527-3	I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	68151-0527-3	I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	68151-0527-3	I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	68151-0527-3	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	68151-0527-3	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	68151-0527-3	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	68151-0527-3	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	68151-0527-3	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	68151-0527-3	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	68151-0527-3	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	68151-0527-3	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded product	product		I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	68151-0527-3	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded product	product		E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	68151-0527-3	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N018655-001	NORPACE CR	DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL		RLD	1982-07-20
N018655-002	NORPACE CR	DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL		RLD, RS	1982-07-20

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 82 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N018655-001	NORPACE CR	EQ 100MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	1982-07-20	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N018655-002	NORPACE CR	EQ 150MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD, RS	1982-07-20	`782e0a99824c…`

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
d08b5e1c-4339-4b83-bd26-a59d84e2a782	Product name	1	20170614

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
68151-0527-3	2020-01-31	C162847	48780-1	9d75b9d0-9ffd-f424-e053-dadaa90a57ce	Norpace disopyramide phosphate capsules Norpace CR disopyramide phosphate extended-release capsules ® ®

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
68151-0527-3	Norpace	1 in 1 PACKAGE	CAPSULE, GELATIN COATED	1		2

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
disopyramide phosphate	ACTIVE INGREDIENT	N6BOM1935W	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
disopyramide	ACTIVE MOIETY	GFO928U8MQ	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
ETHYLCELLULOSES	INACTIVE INGREDIENT	7Z8S9VYZ4B	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
FD&C BLUE NO. 1	INACTIVE INGREDIENT	H3R47K3TBD	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
FD&C RED NO. 3	INACTIVE INGREDIENT	PN2ZH5LOQY	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
GELATIN	INACTIVE INGREDIENT	2G86QN327L	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
SHELLAC	INACTIVE INGREDIENT	46N107B71O	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
SUCROSE	INACTIVE INGREDIENT	C151H8M554	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
TALC	INACTIVE INGREDIENT	7SEV7J4R1U	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
68151-0527	NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [CARILION MATERIALS MANAGEMENT]	2	Legacy NDC, 1 package rows	20140707_f5e0c230-db38-4476-8357-9a227ccff1bc.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Norpace CR	DISOPYRAMIDE PHOSPHATE	Pfizer Laboratories Div Pfizer Inc	e2aa1642-d262-4520-bc6a-9fd3ad795677	2026-03-18	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 018655 application number: NDA018655

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
N6BOM1935W	DISOPYRAMIDE PHOSPHATE	22059-60-5	DISOPYRAMIDE PHOSPHATE

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
309960	disopyramide phosphate 150 MG Oral Capsule	PSN	f5e0c230-db38-4476-8357-9a227ccff1bc	2
209692	Norpace 150 MG Oral Capsule	PSN	f5e0c230-db38-4476-8357-9a227ccff1bc	2
209692	disopyramide 150 MG Oral Capsule [Norpace]	SBD	f5e0c230-db38-4476-8357-9a227ccff1bc	2
309960	disopyramide 150 MG Oral Capsule	SCD	f5e0c230-db38-4476-8357-9a227ccff1bc	2
309960	disopyramide 150 MG (as disopyramide phosphate) Oral Capsule	SY	f5e0c230-db38-4476-8357-9a227ccff1bc	2
209692	Norpace (as disopyramide phosphate) 150 MG Oral Capsule	SY	f5e0c230-db38-4476-8357-9a227ccff1bc	2
209692	Norpace 150 MG Oral Capsule	SY	f5e0c230-db38-4476-8357-9a227ccff1bc	2

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Status
68151-0527-3	68151052703	1 in 1 PACKAGE	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Norpace disopyramide phosphate capsules Norpace CR disopyramide phosphate extended-release capsules ® ®	Carilion Materials Management	2010-02-24	HUMAN PRESCRIPTION DRUG LABEL	2